Net Income

Quebec food distributor Colabor Group fails to secure a financial lifeline, risking creditor protection and threatening a major regional supply chain disruption.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

Rail Vision just secured a key European patent for its AI collision avoidance tech. Is this IP fortress enough to challenge giants and define the future of rail?

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

Talen Energy unveils a major executive overhaul and a novel compensation plan, signaling a strategic pivot to dominate the energy-hungry AI data center market.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

Canada’s condo market is in transition. With prices down and inventory up, a unique opportunity emerges for buyers before a projected 2027 recovery.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

As Sinch appoints Lindy Puttkammer as its new CHRO, the move signals a deep focus on integrating its global workforce and nurturing talent from within.

EfTEN United Property Fund's soaring profits, fueled by a key housing project, highlight a strategic success story amid a recovering Baltic property market.